Hope

ABA 2024 Convention Wraps Up with Resounding Success

Retrieved on: 
Thursday, April 18, 2024
ABA, Hope, Education, Phoenix Rescue Mission, Meeting, Waldorf Astoria New York, Partnership, Policy, Golf, Convention, Growth

Washington, DC, April 18, 2024 (GLOBE NEWSWIRE) -- The recently-concluded American Bakers Association's 2024 Convention in Scottsdale, AZ, was its most successful to date, drawing in nearly 500 industry professionals, bakers, and suppliers.

Key Points: 
  • Washington, DC, April 18, 2024 (GLOBE NEWSWIRE) -- The recently-concluded American Bakers Association's 2024 Convention in Scottsdale, AZ, was its most successful to date, drawing in nearly 500 industry professionals, bakers, and suppliers.
  • “Our Convention served as a dynamic platform for business connections, innovation, and executive thought leadership.
  • With the new strategic plan charting the course, ABA remains steadfast in our commitment to empowering and championing the baking industry, and this year’s Convention was another step in that direction."
  • One of the standout features of the Convention was its unwavering focus to serve as a trusted conduit for business connections.

Energy and Water Development Corp. Secures US Patent Application for Innovative Water Generation Technology

Retrieved on: 
Thursday, April 18, 2024
Hope, Water, IBN, Patent, USC, Renewable energy

This application builds on the international application PCT/EP2021/074299 and aligns with filings in key markets including Canada, Mexico, Brazil, and Colombia.

Key Points: 
  • This application builds on the international application PCT/EP2021/074299 and aligns with filings in key markets including Canada, Mexico, Brazil, and Colombia.
  • The technology outlined in this patent, the Self-Sufficient Energy Supplied System for Generating Atmospheric Water, represents a breakthrough in water resource management, utilizing renewable energy to extract water from atmospheric humidity.
  • This innovative system provides a sustainable alternative to traditional water supplies, crucial for regions plagued by water scarcity.
  • By securing its intellectual property through this patent application, EAWD affirms its position at the forefront of the water solutions industry, offering new hope for sustainable development worldwide.

Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study

Retrieved on: 
Thursday, April 18, 2024
FDA, Dysphagia, Mutation, EDT, Nature, COMP, Oculopharyngeal muscular dystrophy, Hope, Food, News, Death, Yogurt, Pharmacotherapy, Observation, PABPN1, Disease, OPMD, Subject, Ptosis, Patient, EMA, Caregiver, Committee, Clinical trial, Trial of the century, Orphan drug, European Medicines Agency, Pharmaceutical industry

HAYWARD, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announces positive interim clinical data from the 90-day timepoint following the administration of BB-301 to the study’s first subject (Subject 1) treated in the BB-301 Phase 1b/2a single-arm, open-label, sequential, dose-escalation cohort study (NCT06185673) in Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 has been granted Orphan Drug designation by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP).

Key Points: 
  • “To date, no clinical studies have systematically demonstrated a clinical improvement in OPMD patients across both objective and subjective measures of swallowing.
  • We are, therefore, pleased to report positive interim clinical data from multiple radiographic measures as well as subject-reported outcome measures from the first subject treated with BB-301,” said Jerel A.
  • Videofluoroscopic swallowing studies represent the gold standard analytical method for the quantitative assessment of dysphagia (swallowing difficulty) in the clinical setting.
  • The event replay will be placed on the News & Events tab on the Investor page of the Benitec website.

THE NEWS FORUM - Broadcast Exclusive - GLOBAL WARNING – Saturday April 20 and Sunday April 21 at 8PM ET

Retrieved on: 
Thursday, April 18, 2024
The News Forum, Climate change, TNF, Science, Biophysical environment, Politics, Hope, Knowledge, Face, Policy, Entertainment

"Global Warning" delves deep into the nexus of science and politics surrounding the escalating energy demands and the pressing need to safeguard our planet.

Key Points: 
  • "Global Warning" delves deep into the nexus of science and politics surrounding the escalating energy demands and the pressing need to safeguard our planet.
  • Featuring exclusive interviews with eminent scholars and experts, "Global Warning" offers viewers an unprecedented insight into the challenges and opportunities facing humanity in the 21st century.
  • As the world grapples with the existential threat of climate change, "Global Warning" emerges as a beacon of hope and enlightenment.
  • "Global Warning" is slated for broadcast release Saturday April 20 at 8PM ET and will be repeated on Sunday April 21 at 8PM ET.

Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients

Retrieved on: 
Thursday, April 18, 2024
FDA, University, RNA interference, Hospital, Hope, Safety, Survival, Weill Cornell Medicine, Holding, AML, Salvage therapy, Cornell University, D.O, MD Anderson Cancer Center, Patient, Clinical, Medicine, Acute myeloid leukemia, Messenger, Clinical trial, Scripps Health, BH3, Cancer, Pharmaceutical industry

By targeting Bcl-2 at the mRNA level rather than the protein, BP1002 may overcome and prevent some of the mechanisms of resistance that affect venetoclax treatment.

Key Points: 
  • By targeting Bcl-2 at the mRNA level rather than the protein, BP1002 may overcome and prevent some of the mechanisms of resistance that affect venetoclax treatment.
  • The approved treatment cycle is two doses per week over four weeks, resulting in eight doses administered over twenty-eight days.
  • The Phase 1b portion of the study is expected to commence after completion of BP1002 monotherapy cohorts and will assess the safety and efficacy of BP1002 in combination with decitabine in refractory/relapsed AML patients.
  • Gail J. Roboz, M.D., is the National Principal Investigator for the Phase 1/1b trial.

Newsweek and Statista Announce Second Annual America’s Best Fertility Clinics Ranking

Retrieved on: 
Wednesday, April 17, 2024
Statista, Mayo Clinic, Fertility, Hope, CDC, NYU Langone Health, Partnership, Brigham, Newsweek, Infertility, Accreditation, Reproductive medicine, Trust, Patient satisfaction, Birth control

NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Newsweek, the modern global digital news organization, in partnership with Statista, announced today the release of its America’s Best Fertility Clinics rankings.

Key Points: 
  • NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Newsweek, the modern global digital news organization, in partnership with Statista, announced today the release of its America’s Best Fertility Clinics rankings.
  • This is Newsweek’s second annual fertility clinics rankings, which includes 125 of America’s best clinics.
  • With the rise of fertility treatments in America, Newsweek’s rankings provide adults with information about the top clinics to help start or grow their families.
  • “The second annual America’s Best Fertility Clinics ranking has taken on a new meaning to Newsweek due to recent current events.

Muscular Dystrophy Association and Friedreich’s Ataxia Research Alliance Announce Collaborative Research Grant Using Novel Gene Editing Technology to Address Root Cause of Friedreich’s Ataxia Disease

Retrieved on: 
Wednesday, April 17, 2024
Pillar, Enzyme, Friedreich's ataxia, Gene editing, CRISPR, GAA, Hope, Muscular dystrophy, Ataxia, FXN, MDA, Diabetes, FARA, Muscular Dystrophy Association, Column, RNA, Doctor of Philosophy, Research, Scoliosis, Parent, Schnucks, University of Massachusetts, Disease, Therapy, Biomedical Research, Nikolaus Friedreich, Fatigue, Movement, FA, Art, Genome, Organization, Pharmaceutical industry

This funding will further research into using novel genetic technologies to treat Friedreich’s ataxia (FA).

Key Points: 
  • This funding will further research into using novel genetic technologies to treat Friedreich’s ataxia (FA).
  • The grant, Paired Prime Editors to treat Friedreich’s Ataxia, involves prime editing (PE), a next-generation CRISPR gene editing tool that can precisely target the removal of the GAA expansions in the frataxin (FXN) gene.
  • “Our team of investigators is excited to bring multi-disciplinary expertise to the unique challenges of developing PE for FA.
  • This treatment method being targeted – prime editing – aims to directly address the cause of the disease, which is the GAA expansion in the FXN gene.

Finovate Renews Collaboration with IBN’s NetworkNewsWire for FinovateSpring 2024

Retrieved on: 
Wednesday, April 17, 2024
Marriott Marquis, Informa, Social media, Hope, Fintech, NNW, Conference, IBN, Government, Global Operations, Pleasure

Greg Palmer , VP of Finovate, commented, “IBN and NetworkNewsWire have played a vital role in ensuring wider recognition and the success of our events, including FinovateSpring.

Key Points: 
  • Greg Palmer , VP of Finovate, commented, “IBN and NetworkNewsWire have played a vital role in ensuring wider recognition and the success of our events, including FinovateSpring.
  • We are delighted to continue our longstanding collaboration and hope to continue doing so far into the future.
  • Finovate’s team is highly energetic and professional, and it has always been a pleasure to continue our meaningful collaboration with them.
  • We look forward to helping build bridges with new audiences and elevating the visibility of participating companies, speakers, and investors.”

O-I PACKAGING SOLUTIONS AND REVINO ROLL OUT RETURNABLE, REUSABLE GLASS WINE BOTTLES TO PACIFIC NORTHWEST

Retrieved on: 
Tuesday, April 16, 2024
Glass, Hope, Corporate Affairs, Non-governmental organization, Natural Resources, Recycling

O-IPS, a global manufacturer of sustainable glass packaging, will locally produce more than 2.4 million reusable glass wine bottles as part of Revino’s return system.

Key Points: 
  • O-IPS, a global manufacturer of sustainable glass packaging, will locally produce more than 2.4 million reusable glass wine bottles as part of Revino’s return system.
  • Revino was founded to revive the reusable glass bottle ecosystem for beverage producers and consumers.
  • “By extending the use phase of the glass packaging through return and refill winery partnerships, Revino is maximizing the sustainability of packaging for environmentally conscious wine producers.”
    A 2020 study by Zero Waste Europe identified reusable packaging as the most environmentally friendly option.
  • ​​On average, a reusable glass bottle can be reused 25-50 times before being retired and recycled into new glass packaging.

Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting

Retrieved on: 
Tuesday, April 16, 2024
Science, APOE, American Academy, Brain, ABOS, Safety, Hope, Neurogranin, Poster, Plasma, Colorado Convention Center, ES2, GFAP, Patient, Incidence, AAN, CSF, Biomarker, Annual general meeting, Plaque, Cerebrospinal fluid

Acumen is developing sabirnetug as a potential best-in-class antibody treatment for early AD.

Key Points: 
  • Acumen is developing sabirnetug as a potential best-in-class antibody treatment for early AD.
  • Acumen remains on track to initiate the ALTITUDE-AD placebo-controlled Phase 2 trial of sabirnetug in the first half of 2024.
  • Based on safety, target engagement and biomarker data from the INTERCEPT-AD trial, Acumen has determined sabirnetug doses of 35 mg/kg Q4W and 50 mg/kg Q4W in ALTITUDE-AD.
  • Acumen also plans to initiate a Phase 1 bioavailability study to support a subcutaneous dosing option of sabirnetug in mid-2024, as announced in November 2023 .